BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients
Retrieved on:
Tuesday, April 16, 2024
Research, Technology, Medical Devices, Genetics, Health Technology, Biotechnology, Health, Science, Oncology, Artificial Intelligence, NEC, Cancer, Immunotherapy, Recurrence, MD, Tumor microenvironment, Saga University, ICIS, ICI, Patient, IO, Toxicity, Multimedia, Standard of care, Biomarker, EGFR, NSCLC, TME, Lung cancer, Pharmaceutical industry
Still, acquired resistance often leads to recurrence within 1 to 2 years, presenting a challenge for post-treatment optimization.
Key Points:
- Still, acquired resistance often leads to recurrence within 1 to 2 years, presenting a challenge for post-treatment optimization.
- However, combination therapy with ICIs and anti-angiogenic agents has shown promise in EGFR-positive lung cancer.
- By partnering with BostonGene, we aim to uncover novel biomarkers to revolutionize how we approach immunotherapy treatment in EGFR-positive lung cancer, ultimately improving patient outcomes,” said Dr. Naoko Aragane, Professor of Saga University.
- “Our collaboration with Saga University underscores our dedication to advancing the standard of care in Japan by bringing novel technologies to the region.